Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
2013 · The Lancet · 352 citations
https://doi.org/10.1016/s0140-6736(13)60023-9
L
Linda A. DiMeglio
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
464
Papers
25.6K
Citations
83
h-index
224
i10-index
Linda A. DiMeglio is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Diabetes Management and Research & Diabetes and associated disorders & Pancreatic function and diabetes. The author has an h-index of 83, co-authored 395 publications.
ORCID: 0000-0002-8033-6078Papers by this author
worksSecond international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine
2023 · Nature Medicine · 187 citations
https://doi.org/10.1038/s41591-023-02502-5
A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk
2018 · Diabetes Care · 165 citations
https://doi.org/10.2337/dc18-0087
A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk
2018 · Diabetes Care · 165 citations
https://doi.org/10.2337/dc18-0087
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2021 · The Lancet Diabetes & Endocrinology · 123 citations
https://doi.org/10.1016/s2213-8587(21)00139-x
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2021 · The Lancet Diabetes & Endocrinology · 123 citations
https://doi.org/10.1016/s2213-8587(21)00139-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat